| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | RPTX | Common Shares | Sale | -$547K | -16.7K | -0.39% | $32.67 | 4.22M | May 28, 2021 | See Footnote | F1, F2, F3, F4 |
| transaction | RPTX | Common Shares | Sale | -$492K | -15.1K | -0.36% | $32.50 | 4.21M | Jun 1, 2021 | See Footnote | F1, F5, F6, F7 |
| transaction | RPTX | Common Shares | Sale | -$188K | -5.92K | -0.14% | $31.83 | 4.2M | Jun 2, 2021 | See Footnote | F1, F8, F9, F10 |
| transaction | RPTX | Common Shares | Sale | -$9.63K | -297 | -0.01% | $32.42 | 4.2M | Jun 2, 2021 | See Footnote | F1, F11, F12, F13 |
| Id | Content |
|---|---|
| F1 | Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021. |
| F2 | The shares were sold as follows: 7,131 by MPM BioVentures 2014, L.P. ("BV 2014"), 246 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 9,365 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). |
| F3 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.04 to $32.89 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F4 | The shares are held as follows: 2,182,128 by BV 2014, 135,843 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 75,110 by AM BV2014 and 1,830,849 by UBS Oncology. MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. Ansbert Gadicke is a managing director of BV LLC. MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is the Managing Member of Oncology GP LLC. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. |
| F5 | The shares were sold as follows: 6,449 by BV 2014, 222 by AM BV2014 and 8,470 by UBS Oncology. |
| F6 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.12 to $32.98 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F7 | The shares are held as follows: 2,175,679 by BV 2014, 135,843 by BV 2014(B), 74,888 by AM BV2014 and 1,822,379 by UBS Oncology. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. |
| F8 | The shares were sold as follows: 2,521 by BV 2014, 87 by AM BV2014 and 3,310 by UBS Oncology. |
| F9 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.29 to $32.24 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F10 | The shares are held as follows: 2,173,158 by BV 2014, 135,843 by BV 2014(B), 74,801 by AM BV2014 and 1,819,069 by UBS Oncology. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. |
| F11 | The shares were sold as follows: 126 by BV 2014, 4 by AM BV2014 and 167 by UBS Oncology. |
| F12 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.31 to $32.58 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F13 | The shares are held as follows: 2,173,032 by BV 2014, 135,843 by BV 2014(B), 74,797 by AM BV2014 and 1,818,902 by UBS Oncology. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. |